Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ann Arbor Stage III Hodgkin Lymphoma”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Testing effectiveness (Phase 2)Looking for participantsNCT06471738
What this trial is testing

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

Who this might be right for
Ann Arbor Stage II Follicular LymphomaGrade 1 Follicular LymphomaAnn Arbor Stage III Follicular Lymphoma+3 more
Chinese PLA General Hospital 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT00972478
What this trial is testing

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Who this might be right for
Ann Arbor Stage II Non-Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma
National Cancer Institute (NCI) 83
Testing effectiveness (Phase 2)Study completedNCT01286272
What this trial is testing

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Who this might be right for
Ann Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular Lymphoma+4 more
National Cancer Institute (NCI) 135
Testing effectiveness (Phase 2)Active Not RecruitingNCT03155620
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+42 more
National Cancer Institute (NCI) 1,377
Large-scale testing (Phase 3)Active Not RecruitingNCT04799275
What this trial is testing

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Who this might be right for
Ann Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IIX (Bulky) Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma+18 more
National Cancer Institute (NCI) 422
Early research (Phase 1)WithdrawnNCT03217253
What this trial is testing

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

Who this might be right for
Ann Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaMetastatic Malignant Solid Neoplasm+8 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Active Not RecruitingNCT02166463
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Who this might be right for
Ann Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage IIIB Hodgkin LymphomaAnn Arbor Stage IVA Hodgkin Lymphoma+3 more
National Cancer Institute (NCI) 600
Testing effectiveness (Phase 2)Active Not RecruitingNCT05025800
What this trial is testing

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Aggressive B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular Lymphoma+17 more
M.D. Anderson Cancer Center 47
Testing effectiveness (Phase 2)Study completedNCT02532257
What this trial is testing

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

Who this might be right for
Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular Lymphoma+7 more
M.D. Anderson Cancer Center 48
Testing effectiveness (Phase 2)Study completedNCT03213665
What this trial is testing

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT01979536
What this trial is testing

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveAnn Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell LymphomaAnn Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma+1 more
National Cancer Institute (NCI) 137
Testing effectiveness (Phase 2)Looking for participantsNCT06442475
What this trial is testing

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Who this might be right for
Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular Lymphoma+6 more
University of Washington 20
Very early researchLooking for participantsNCT04139304
What this trial is testing

Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Who this might be right for
Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell Lymphoma+2 more
AIDS Malignancy Consortium 15
Testing effectiveness (Phase 2)Study completedNCT00654732
What this trial is testing

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Who this might be right for
Classic Hodgkin LymphomaLugano Classification Stage III Hodgkin Lymphoma AJCC v8Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
M.D. Anderson Cancer Center 58
Testing effectiveness (Phase 2)Study completedNCT03213678
What this trial is testing

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+30 more
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT02494700
What this trial is testing

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

Who this might be right for
Ann Arbor Stage I B-Cell Non-Hodgkin LymphomaAnn Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular Lymphoma+20 more
M.D. Anderson Cancer Center 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT02758717
What this trial is testing

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Who this might be right for
Ann Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage II Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin Lymphoma+8 more
Academic and Community Cancer Research United 46
Early research (Phase 1)Active Not RecruitingNCT04323956
What this trial is testing

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Who this might be right for
Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone Lymphoma+11 more
Mayo Clinic 50
Testing effectiveness (Phase 2)Study completedNCT03213691
What this trial is testing

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+8 more
National Cancer Institute (NCI) 21
Testing effectiveness (Phase 2)Study completedNCT03220035
What this trial is testing

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more
National Cancer Institute (NCI) 4
Next Page